MétaCan
Menu
Back to cohort
Record W3004164092 · doi:10.1186/s13063-019-3846-x

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

2020· article· en· W3004164092 on OpenAlexaff
Yaseen M. Arabi, Ayed Y. Asiri, Abdullah M. Assiri, Hani Jokhdar, Adel Alothman, Hanan H. Balkhy, Sameera Aljohani, Shmeylan Al Harbi, Suleiman Kojan, Majed Al Jeraisy, Ahmad Deeb, Ziad A. Memish, Sameeh Ghazal, Sarah Al Faraj, Fahad Al-Hameed, Asim Alsaedi, Yasser Mandourah, Ghaleb A. Al Mekhlafi, Nisreen Murad Sherbeeni, Fatehi Elzein, Abdullah Almotairi, Ali Al Bshabshe, Ayman Kharaba, Jesna Jose, Abdulrahman Al Harthy, Mohammed Al Sulaiman, Ahmed Mady, Robert Fowler, Frederick G. Hayden, Abdulaziz Al‐Dawood, M. A. Abdelzaher, Wail Bajhmom, Mohamed Hussein

Bibliographic record

VenueTrials · 2020
Typearticle
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsSunnybrook HospitalUniversity of Toronto
FundersSchool of Medicine, University of North Carolina at Chapel HillUniversity of North Carolina at Chapel HillSchool of Medicine, Emory UniversityKing Abdullah International Medical Research CenterEmory University
KeywordsLopinavirMedicineRandomized controlled trialRitonavirPlaceboInternal medicineClinical trialLopinavir/ritonavirImmunologyViral loadHuman immunodeficiency virus (HIV)Alternative medicineAntiretroviral therapyCoronavirus disease 2019 (COVID-19)PathologyDisease

Abstract

fetched live from OpenAlex

The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02845843. Registered on 27 July 2016.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.056
metaresearch head score (Gemma)0.064
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.056
Threshold uncertainty score0.296

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0560.064
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0050.005
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0030.005
Insufficient payload (model declined to judge)0.0110.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.244
GPT teacher head0.424
Teacher spread0.180 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations132
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueTrialsSame topicHepatitis C virus researchFrench-language works237,207